New year, new product, new profit

As we approach the new year, there’s an exciting opportunity right at your pharmacy’s doorstep. Denosumab, the generic, is coming off patent. This shift allows your pharmacy to explore biosimilar options.

Currently, while 67% of Denosumab prescriptions are already generic, many GPs prescribe branded versions. It’s essential to ensure continuity with these brands to maintain trust and care quality.

And Numark members, here’s the upside: PHOENIX offers access to this new product at favourable pricing, giving you improved margin against the brand!

This means better margins for you and cost savings for your patients—truly a win-win! Let’s make 2026 a year of growth and continued excellence in patient care.

Order now via your usual ordering route.

For more information on Jubbonti® 60 mg solution for injection in pre-filled syringe, please see the links to the SPC and PIL here:

Jubbonti® 60 mg solution for injection in pre-filled syringe PIL

Jubbonti® 60 mg solution for injection in pre-filled syringe SPC